142 related articles for article (PubMed ID: 35114276)
1. Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.
Date Y; Taniuchi I; Ito K
Gene; 2022 Apr; 819():146234. PubMed ID: 35114276
[TBL] [Abstract][Full Text] [Related]
2. Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
Kilbey A; Terry A; Wotton S; Borland G; Zhang Q; Mackay N; McDonald A; Bell M; Wakelam MJ; Cameron ER; Neil JC
J Cell Biochem; 2017 Jun; 118(6):1432-1441. PubMed ID: 27869314
[TBL] [Abstract][Full Text] [Related]
3. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
4. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
5. Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.
Hay J; Gilroy K; Huser C; Kilbey A; Mcdonald A; MacCallum A; Holroyd A; Cameron E; Neil JC
J Cell Biochem; 2019 Oct; 120(10):18332-18345. PubMed ID: 31257681
[TBL] [Abstract][Full Text] [Related]
6. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
7. Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma.
Otani S; Date Y; Ueno T; Ito T; Kajikawa S; Omori K; Taniuchi I; Umeda M; Komori T; Toguchida J; Ito K
Oncogene; 2022 Jan; 41(5):683-691. PubMed ID: 34803166
[TBL] [Abstract][Full Text] [Related]
8. Roles of AML1/RUNX1 in T-cell malignancy induced by loss of p53.
Shimizu K; Yamagata K; Kurokawa M; Mizutani S; Tsunematsu Y; Kitabayashi I
Cancer Sci; 2013 Aug; 104(8):1033-8. PubMed ID: 23679839
[TBL] [Abstract][Full Text] [Related]
9. C/ebpα represses the oncogenic Runx3-Myc axis in p53-deficient osteosarcoma development.
Omori K; Otani S; Date Y; Ueno T; Ito T; Umeda M; Ito K
Oncogene; 2023 Aug; 42(33):2485-2494. PubMed ID: 37402881
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.
Zwolinska AK; Heagle Whiting A; Beekman C; Sedivy JM; Marine JC
Oncogene; 2012 Jul; 31(28):3311-21. PubMed ID: 22081066
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal location targets different MYC family gene members for oncogenic translocations.
Gostissa M; Ranganath S; Bianco JM; Alt FW
Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2265-70. PubMed ID: 19174520
[TBL] [Abstract][Full Text] [Related]
13. Deletion of Irf5 protects hematopoietic stem cells from DNA damage-induced apoptosis and suppresses γ-irradiation-induced thymic lymphomagenesis.
Bi X; Feng D; Korczeniewska J; Alper N; Hu G; Barnes BJ
Oncogene; 2014 Jun; 33(25):3288-97. PubMed ID: 23912454
[TBL] [Abstract][Full Text] [Related]
14. Runx1 promotes B-cell survival and lymphoma development.
Blyth K; Slater N; Hanlon L; Bell M; Mackay N; Stewart M; Neil JC; Cameron ER
Blood Cells Mol Dis; 2009; 43(1):12-9. PubMed ID: 19269865
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma.
De la Cueva E; García-Cao I; Herranz M; López P; García-Palencia P; Flores JM; Serrano M; Fernández-Piqueras J; Martín-Caballero J
Oncogene; 2006 Jul; 25(29):4128-32. PubMed ID: 16462758
[TBL] [Abstract][Full Text] [Related]
16. Functional relationship between p53 and RUNX proteins.
Bae SC; Kolinjivadi AM; Ito Y
J Mol Cell Biol; 2019 Mar; 11(3):224-230. PubMed ID: 30535344
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.
Grabow S; Waring P; Happo L; Cook M; Mason KD; Kelly PN; Strasser A
Cell Death Differ; 2012 Apr; 19(4):623-32. PubMed ID: 21997189
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for the tissue specificity of β-catenin oncogenesis.
Sharma A; Sen JM
Oncogene; 2013 Apr; 32(15):1901-9. PubMed ID: 22689057
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
[TBL] [Abstract][Full Text] [Related]
20. The glucocorticoid receptor is increased in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells, and its nuclear translocation counteracts c-myc expression.
Yan M; Kuang X; Scofield VL; Shen J; Lynn WS; Wong PK
Steroids; 2007 May; 72(5):415-21. PubMed ID: 17418878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
